In this article, analytical chemist Venkata Ranga Rao Attaluri explores the ongoing challenges posed by nitrosamine contamination in pharmaceuticals, highlighting the importance of robust and sensitive analytical detection methods.
In 2018 the discovery of unacceptable levels of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) in angiotensin receptor blockers (ARBs) triggered increased regulatory focus on nitrosamines (NAs). Acceptable intake (AI) levels have since been established for a range of NAs with regulators (European Medicines Agency (EMA) and US Food and Drug Administration (FDA)) calling for submissions for any associated changes in existing market authorisations by 1 October 2023.1-2 This article considers the issues associated with meeting demand for appropriately sensitive analysis and includes details of a demonstrated method for NDMA detection in extended release (ER) metformin tablets.
The issue of NA contamination
NAs are characterised by both nitroso (N=O) and amine (NH2) functionality. Collectively referred to as a ‘cohort of concern’ by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), multiple NAs are classified as ‘probable human carcinogens’ by the International Agency for Research on Cancer (IARC). Following the initial 2018 ARB-related incident, NAs have been discovered in a range of pharmaceutical products, including ranitidine and metformin. To date, more than 1,400 batches have been recalled in efforts to minimise the associated risk to human health.2
NA contamination can occur in multiple ways; such as from by-product reactions associated with the use of nitrosating agents, the introduction of specific raw materials, manufacturing steps such as quenching, or progressive synthesis during storage. Identifying and controlling the root cause of NA contamination can therefore be challenging. Even relatively subtle process changes, such as a switch to alternative, more cost-effective reagents or the adoption of solvent recycling strategies, can prove problematic.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
The FDA originally highlighted just seven NAs that could theoretically be present in pharmaceutical products, but the scope of concern has since broadened. The latest guidance includes AI limits for a wide range of nitrosamine drug substance‑related impurities (NDSRIs) reflecting growing concern over these product-specific contaminants. Indeed, NDSRI contamination has recently triggered two relatively high-profile product withdrawals: Orphenadrine Citrate tablets (Sandoz)3 and Quinapril HCl/Hydrochlorothiazide (Pfizer).4 More generally, regulation around NA contamination continues to evolve with the EMA issuing new guidance as recently as October 2023.1
The relative speed with which NA detection requirements have been established has left some scrambling to establish in-house capability and, more generally, threatened to severely test industry capacity for trace analysis. The 26.5ng per day AI levels established for compounds of most concern, such as NDEA, reflect their potential to cause harm at levels as low as parts per billion (ppb) but present a significant analytical challenge when it comes to robust detection. Contract providers have an important role to play in meeting this demand and have invested significant time and resources to the development and validation of advanced methods for detection that combine sensitivity, speed and flexibility.
Sensitivity
Liquid chromatography-mass spectrometry (LC/MS), LC/MS-N (multistage MS) and LC-High Resolution MS (HRMS) all have proven sufficiently sensitive for NA detection, with appropriate method development. Combining LC and MS brings the orthogonality needed for accurate detection at the lowest contaminant levels and addresses the challenge of isobaric species. Optimisation of the LC step with appropriate reference standards is critical when it comes to addressing solubility issues and mass suppression from excipient species; advanced extraction techniques can help to minimise sample loss, enhance recovery efficiency and keep NAs intact for identification. Robust atmospheric pressure chemical ionisation (APCI) can mitigate the ionisation effects caused by complex and variable sample matrices.
Speed
LC/MS techniques are also appealing from the perspective of speed and efficiency. The need to retrospectively analyse authorised products creates a significant analytical burden, but so too does the extension of measurement into new chemical entity development, where there is scope for process alteration. By minimising sample preparation, for example via direct injection or direct sample analysis, and adopting other streamlining strategies, LC/MS techniques can be shaped for relatively high productivity.
Flexibility
Flexible and robust methods are critical given the need to detect and quantify a wide range of NAs, NA precursors and NDSRIs in a multiplicity of drug products. Furthermore, each specific NA – drug combination requires a unique method and associated validation. Both triple quadrupole mass spectrometry (TQ‑MS) and HRMS platforms are valuable in this respect and a good choice when implementing LC/MS methods. That said, there are scenarios where even TQ systems may struggle; for instance, when dealing with drugs with a high maximum daily dose (MDD) for which AI specifications push detection techniques to their limit.
The validation guidelines shown in Table 1 are useful in supporting the development of methods that meet requirements and provide a useful checklist with respect to sensitivity, speed and flexibility.
Parameter
Purpose
Acceptance Criteria
System precision
Ensures the consistency and reproducibility of the analytical system.
n Relative standard deviation (RSD) of peak area responses from six replicate injections of Level-4 standard solution: ≤ 15%
System suitability
Ensures accuracy and reliability in quantifying impurities across the linear range.
n Cumulative RSD of impurity peak area responses (including bracketing standards): ≤ 20%
n Correlation coefficient (r) for impurity peak: ≥ 0.98
Accuracy
Provides measurements closely aligned with the actual analyte concentrations.
n Recovery at each level: 70% – 130%
n % RSD for LOQ: ≤ 30%
n % RSD for all other levels: ≤ 25%
Limit of quantitation (LOQ)
Ensures robust and accurate detection down to low concentrations.
n LOQ: 1.0049 ng/mL (0.01005 ppm)
n RSD of peak area response for six injections of LOQ solution: ≤ 25%
n Signal to noise ratio for NDMA peak in LOQ solution: ≥ 10
Limit of detection (LOD)
Ensures robust and accurate detection down to low concentrations.
n Average signal-to-noise ratio: NLT 3
Specificity
Confirms the method’s ability to detect and quantify the impurity, free from interference.
n Peak area in blank at impurity peak retention time < peak area in LOD solution
Repeatability/Intermediate precision/Ruggedness
Demonstrates reliability and consistency in measuring impurity content.
n RSD for impurity content from six samples: ≤ 15.0%
n Cumulative RSD for 12 samples from Repeatability and Intermediate
precision: ≤ 20.0%
Stability of standard and sample solution
Ensures stability over time, leading to accurate and reliable measurements.
n Percent recovery of stability standard for standard solutions: 80% – 120%
n Percent difference between impurity content in initial and stability sample: within 20.0%
Robustness
Ensures minor variations in experimental conditions do not significantly impact accuracy and precision.
n RSD of peak area response for impurity peak from six replicate injections of Level-4 standard solution: ≤ 15%
Table 1: Validation criteria checklist
Case study: using TQ LC/MS/MS for the detection of NDMA
Linearity data for an LC/MS/MS method (TQ, AB Sciex API 6500) optimised and validated for the detection of NDMA in ER metformin hydrochloride tablets (500 and 1,000mg) is shown in Figure 2 and Table 2. The method was developed from a published FDA method utilising LC/HRMS5 with the aim of demonstrating the utility of a TQ system for this application.
Linearity samples
Actual Concentration (ng/mL)
NDMA Area (counts)
Calculated Concentration (ng/mL)
% Accuracy
Level 1
1.0049
33,761
1.0268
102
Level 2
2.5123
80,485
2.3614
94
Level 3
5.0245
172,418
4.9874
99
Level 4
7.5368
265,518
7.6467
101
Level 5
10.0490
351,394
10.0996
101
Level 6
20.0980
719,790
20.6225
103
Slope
35000
Y-Intercept
-2190
r
0.9992
Table 2: Associated metrics for LC/MS/MS NDMA detection method
Figure 2: Linearity plot for LC/MS/MS NDMA detection method.
The method demonstrates excellent linearity across the concentration range spanned by the six calibration standards, which runs from one to 20 ng/ml. Accuracy is well within the acceptance criteria for each standard (80-120 percent), notably so for the most dilute, Level 1, Limit of Quantification (LOQ) solution (70-130 percent); the correlation coefficient r=0.9992 also meets the acceptance criteria (r not less than 0.98). The gradient of the curve (slope 35,000) indicates good sensitivity.
Table 3 shows data from repeat measurements of the LOQ calibration standard. The percentage relative standard deviation (RSD) of six percent is well within the acceptance criteria limits (not more than 25 percent) and the signal‑to-noise ratio is above the minimum value of 10 specified. The method therefore has a confirmed LOQ of 0.01005ppm and a limit of detection (LOD) as determined using the signal-to-noise ratio method of 0.00301ppm.
LOQ Concentration
0.01005 ppm w.r.t sample
1.0049 ng/mL
Injection
Peak Area
s/n ratio
1
33,108
28.1
2
32,132
84.2
3
30,216
25.6
4
34,823
10.4
5
30,506
15.5
6
35,030
32.6
Mean
32,636
33
% RSD (for peak area)
6
NA
Table 3: Repeat measurements of the LOQ calibration standard
Via rigorous validation testing the optimised method was shown to meet all the validation criteria and was subsequently used successfully for product testing. The LOQ and LOD figures for the method are especially noteworthy given the FDA requirement of an LOQ of 0.03ppm for products with a MDD < 880 mg/day, where the AI is 26.5 ng/day, and the most stringent EMA requirement of an LOQ ≤10 percent of the level indicated by the AI, where the ppm level of interest is determined by dividing the AI by MDD.6
Conclusion
The regulatory focus on NAs and NDSRIs has rapidly intensified and continues to evolve. It creates a need for highly sensitive analysis for samples that vary considerably with respect to the analyte of interest and associated matrix. Contract service providers have the expertise to help the industry develop and apply relevant methods to meet the significant analytical burden efficiently and at pace. Case studies such as the one presented here showcase their capabilities.
About the author
Venkata Ranga Rao Attaluri
An accomplished analytical research scientist with more than seven years of experience, Venkata Ranga Rao Attaluri specialises in the research, development and validation of analytical and bio-analytical methods tailored for pharmaceutical industries. As an analytical and bio-analytical chemist at Sannova Analytical LLC since 2018, he has demonstrated expertise in utilising a range of sophisticated instruments for method development and validation. In addition to nitrosamine testing, his focus includes extractable and leachable studies, employing LCMS, HPLC, GCMS, Headspace-GCMS and ICP-MS, as well as analysis of unknown compounds and mass confirmation using LCMS/MS.
References
1. ‘Question and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products’ EMA/409815/2020 Rev.19. [Internet] European Medicines Agency. 2023. [cited 2024Jan]. Available from: https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-questions-and-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf
2. Guidance for Industry ‘Control of Nitrosamine Impurities in Human Drugs’ Rev 1. [Internet] US Food and Drug Administration, Center for Drug Evaluation and Research. 2021.
[cited 2024Jan]. Available from: https://www.fda.gov/media/141720/download
3. Company Announcement ‘Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity’. [Internet] FDA. 2022. [cited 2024Jan]. Available from: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-nationwide-recall-13-lots-orphenadrine-citrate-100-mg-extended-release-tablets-due
4. Company Announcement ‘Pfizer Voluntary Nationwide Recall of Lots of ACCURETICTM (Quinapril HCl/Hydrochlorothiazide), Quinapril and Hydrochlorothiazide Tablets, and Quinapril HCl/Hydrochlorothiazide Tablets Due to N-Nitroso-Quinapril Content’. [Internet] FDA. 2022. [cited 2024Jan]. Available from: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pfizer-voluntary-nationwide-recall-lots-accuretic-quinapril-hclhydrochlorothiazide-quinapril-and
5. Liquid Chromatography-Electrospray Ionization-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Nitrosamine Impurities in Metformin drug Substance and Drug Product. [Internet] US Food and Drug Administration. 2020. [cited 2024Jan]. Available from: https://www.fda.gov/media/138617/download
6. Guidance on Nitrosamine Impurities. [Internet] Indian Pharmaceutical Alliance. 2022. [cited 2024Jan]. Available from: https://www.ipa-india.org/wp-content/uploads/2023/07/guideline-05072023c.pdf
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.